logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO 2019 — Carfilzomib regimens show advantage in frail patients with multiple myeloma

Post hoc analysis of frailty subgroups from phase 3 ASPIRE and ENDEAVOR.